Radiologic Progression of Interstitial Lung Abnormalities following Surgical Resection in Patients with Lung Cancer
1
Department of Radiology, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul 05030, Republic of Korea
2
Research Coordinating Center, Konkuk University Medical Center, Seoul 05030, Republic of Korea
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2023, 12(21), 6858; https://doi.org/10.3390/jcm12216858
Submission received: 14 September 2023
/
Revised: 26 October 2023
/
Accepted: 27 October 2023
/
Published: 30 October 2023
(This article belongs to the Section Nuclear Medicine & Radiology)
Abstract
:In this study, we aimed to assess the prevalence of interstitial lung abnormalities (ILAs) and investigate the rates and risk factors associated with radiologic ILA progression among patients with lung cancer following surgical resection. Patients who underwent surgical resection for lung cancer at our institution from January 2015 to December 2020 were retrospectively evaluated and grouped according to their ILA status as having no ILAs, equivocal ILAs, or ILAs. Progression was determined by simultaneously reviewing the baseline and corresponding follow-up computed tomography (CT) scans. Among 346 patients (median age: 67 (interquartile range: 60–74) years, 204 (59.0%) men), 22 (6.4%) had equivocal ILAs, and 33 (9.5%) had ILAs detected upon baseline CT. Notably, six patients (6/291; 2.1%) without ILAs upon baseline CT later developed ILAs, and 50% (11/22) of those with equivocal ILAs exhibited progression. Furthermore, 75.8% (25/33) of patients with ILAs upon baseline CT exhibited ILA progression (76.9% and 71.4% with fibrotic and non-fibrotic ILAs, respectively). Multivariate analysis revealed that ILA status was a significant risk factor for ILA progression. ILAs and equivocal ILAs were associated with radiologic ILA progression after surgical resection in patients with lung cancer. Hence, early ILA detection can significantly affect clinical outcomes.
1. Introduction
Interstitial lung abnormalities (ILAs) refer to the incidental findings of computed tomography (CT) abnormalities without clinical suspicion of interstitial lung disease (ILD). They have been increasingly emphasized and recognized in recent years owing to their clinical impact, potential for progression to clinically significant ILD, and association with adverse clinical outcomes, such as all-cause mortality [1].
Old age and prolonged tobacco smoke exposure, which are both common among patients with idiopathic pulmonary fibrosis, along with other factors, such as occupational or environmental hazards and genetic predisposition, have been identified as risk factors for ILAs [2]. Overlapping risk factors highlight ILAs in patients with lung cancer. They are associated with an increased prevalence and mortality in populations with a high prevalence of smoking, such as lung cancer screening or chronic obstructive pulmonary disease populations, as well as in the general population [3,4,5,6,7]. Additionally, ILAs should be considered important in patients with lung cancer because of the increased risk of complications with cancer treatments, including surgery, chemotherapy, and radiotherapy [2,8,9,10]. The prevalence and clinical course of ILAs in patients with lung cancer need to be better understood to provide appropriate monitoring and improve patient prognosis.
Studies have been conducted on ILA progression in patient cohorts, including the National Lung Screening Trial (NLST) [3]; however, studies on ILA progression over time, specifically in patients with lung cancer, are lacking. This leaves a knowledge gap regarding radiologic progression and associated risk factors in this patient group.
Therefore, the aim of this study was to investigate the prevalence of ILAs and the rate and risk factors of radiologic ILA progression in patients with lung cancer following surgical resection.
2. Materials and Methods
2.1. Study Population
Among the 418 consecutive patients who underwent surgical resection for lung cancer at our institution from January 2015 to December 2020, we excluded patients with a history of thoracic operations (n = 34), those with a previous diagnosis of lung cancer (n = 1), those without a follow-up CT (n = 8), those with only short-term follow-up CTs within 90 days (n = 13), those whose final diagnosis was not lung cancer (n = 11), and those with a previous diagnosis of ILD (n = 5). As a result, 346 patients were included in this study (Figure 1).
This retrospective study was approved by the Institutional Review Board of Konkuk University Medical Center. The requirement for written informed consent was waived owing to the retrospective nature of the study.
2.2. Data Collection
Patient-related demographics, including age, sex, smoking history, pulmonary function tests (the forced expiratory volume in the first second (FEV1), forced vital capacity (FVC), and FEV1/FVC ratio), tumor histology, stage, extent, and multiplicity of surgery, treatment options (chemotherapy and radiation therapy) and ILD diagnosis during follow-up, were collected from the electronic medical record system. Pathological staging was reevaluated according to the eighth edition of the tumor, node, and metastasis staging system. Anticancer drugs were classified as cytotoxic chemotherapy, oncogene-targeted agents, and immunotherapy.
2.3. CT Protocol
Chest CT scans were obtained using the following multidetector CT scanners, each with more than 16-section channels: Optima 660CT (GE Healthcare, Chicago, IL, USA), LightSpeed VCT (GE Healthcare), Revolution Apex (GE Healthcare), SOMATOM Definition (Siemens Healthineers, Erlangen, Germany), and SOMATOM Force (Siemens Healthineers). Images were obtained during breath-holding with full inspiration in the supine position. The slice thickness used at our hospital was 1.0–2.5 mm.
2.4. CT Image Evaluation
The baseline chest CT images obtained at the time of lung cancer diagnosis and the last follow-up chest CT images were retrospectively reviewed. Two thoracic radiologists (Y.J.S. and S.Y.A., with 5 and 8 years of experience in thoracic imaging, respectively), blinded to the clinical data, independently reviewed the CT images to determine the presence of ILAs. ILAs were scored using a 3-point scale (“0”, no evidence of ILAs; “1”, equivocal ILAs; and “2”, ILAs). Using a modified sequential reading method, each radiologist initially reviewed half of the total CT scans independently. After this initial review, they cross-read each other’s scans that were scored as either 1 or 2. Additionally, 20% of the scans that were initially scored as 0 by one radiologist were also cross-reviewed by the other [5,11,12].
ILAs were defined as the presence of any non-dependent abnormality affecting >5% of any lung zone, including ground glass or reticular abnormalities, architectural distortion, traction bronchiectasis, non-emphysematous cysts, and honeycombing (score 2) [2]. ILAs affecting <5% of any lung zone or that were unilateral were defined as equivocal ILAs (score 1). ILAs were further classified into the following two subcategories, modifying from the classification in the Position Paper by the Fleischner Society [2]: (i) fibrotic ILAs (ILAs with traction bronchiectasis, architectural distortion, and honeycombing, providing evidence of lung fibrosis) and (ii) nonfibrotic ILAs.
The baseline and corresponding follow-up CT scans were simultaneously reviewed to determine progression [13]. Progression was defined as an increase in the lung area or a new appearance of an interstitial abnormality (Figure 2). Progression was assessed only in patients with an ILA score of 2 on the follow-up CT. In the case of a discrepancy between the two raters, the final decision was made by consensus.
The ILA status and lesion characteristics, including the lesion size and type (solid, part-solid, and ground glass opacity), were recorded.
2.5. Statistical Analysis
Patient demographics were compared between patients with ILAs and those with equivocal ILAs and no ILAs using the Wilcoxon rank-sum test for continuous variables and the chi-squared or Fisher’s exact tests for categorical variables. Post-hoc analysis was performed using the Bonferroni method; thus, p-values were calculated by dividing the raw p-values by the number of comparisons. Univariate and multivariate logistic regression analyses were performed to identify factors associated with ILA progression.
Variables with p-values < 0.5 in the univariate analyses were included in the multivariate analysis. p-values < 0.05 in the multivariate analysis were considered statistically significant. Cohen’s kappa agreement was used to assess the interrater agreement for each ILA status and progression. CT scans with an ILA score of 2 were analyzed for agreement with the type of ILA. Interrater agreement was classified as poor (κ = 0–0.20), fair (κ = 0.21–0.40), moderate (κ = 0.41–0.60), good (κ = 0.61–0.80), or excellent (κ = 0.81–1.00). The reported p-values are two-sided, and those <0.05 were considered statistically significant. Statistical analyses were performed using the R software (version 4.2.1; R Foundation for Statistical Computing, Vienna, Austria).
3. Results
3.1. Patient Demographics and ILA Status
The demographic characteristics and ILA status of patients at the baseline chest CT are summarized in Table 1 and Table S1. The median age of the study population was 67 (interquartile range (IQR): 60–74) years. Among the total 346 patients, 204 (59.0%) were men, and the former and current smokers constituted 110 (32.3%) and 85 (24.9%), respectively. Most patients were diagnosed with adenocarcinoma (79.8%), presented with stage I cancer (68.2%), and underwent lobectomy (71.4%). Of these patients, 166 (48.0%) and 33 (9.5%) received chemotherapy and radiotherapy, respectively.
Patients with ILAs (n = 33) were significantly older, more likely to be male, more likely to be a former or current smoker, more likely to have solid-type lung cancer, more likely to be diagnosed with squamous cell carcinoma or others, and less likely to receive oncogene-targeted therapy than patients without ILAs. Patients with equivocal ILAs (n = 22) were significantly older, more likely to have an FEV1/FVC ratio ≤70, and more likely to be diagnosed with squamous cell carcinoma or others than patients without ILAs. No significant differences were observed in operation type, cancer stage, radiotherapy, or follow-up period between the groups.
3.2. Factors Associated with ILA Progression
The median time between baseline and the last follow-up CT scan was 1313 (IQR: 945–1683) days. Six patients (6/291; 2.1%) without ILAs on baseline CT images developed ILAs, and 11 patients (11/22, 50.0%) with equivocal ILAs exhibited ILA progression. Twenty-five patients with ILAs on baseline CT images (25/33; 75.8%) exhibited ILA progression (20 of 26 [76.9%] patients with fibrotic ILAs and 5 of 7 [71.4%] with nonfibrotic ILAs). Among the entire cohort, six patients were diagnosed with ILD during the follow-up period: one with equivocal ILAs (1/22, 4.5%) and five with fibrotic ILAs (5/26, 19.2%).
Univariate and multivariate analyses of the associations between the clinical and radiologic factors and ILA progression are summarized in Table 2. Univariate analysis revealed that older age, male sex, former and current smoking, wedge and segmentectomy, solid lesion type, squamous cell carcinoma and others, adjuvant immunotherapy, and ILA status were significant risk factors for ILA progression. ILA status on baseline CT images was the only significant risk factor for ILA progression in the multivariate analysis (adjusted odds ratio (OR): 35.964, 95% confidence interval (CI): 10.033–147.398, p < 0.001 for equivocal ILAs; adjusted OR: 200.862, 95% CI: 22.823–4595.382, p < 0.001 for nonfibrotic ILAs; adjusted OR: 114.855, 95% CI: 29.377–561.518, p < 0.001 for fibrotic ILAs).
3.3. Interrater Agreement
Interrater agreement for the determination of the ILA status on baseline and follow-up CT scans was deemed good, with κ values of 0.717 and 0.787, respectively. For the categorization of ILA type, the agreement was excellent for baseline CT (κ = 0.904) and moderate for follow-up CT (κ = 0.574) images. The agreement for assessment of ILA progression was moderate (κ = 0.509).
4. Discussion
In this retrospective study, we assessed the prevalence and radiologic progression of ILAs in patients with lung cancer who underwent surgical resection. The study demonstrated that approximately 6.4% (22/346) of patients had equivocal ILAs, and 9.5% (33/346) had ILAs on baseline CT images. Furthermore, 2.1% (6/291), 50.0% (11/22), and 75.8% (25/33) of patients with no ILAs, equivocal ILAs, and ILAs, respectively, on CT images at the time of lung cancer diagnosis were observed to have ILA progression on the final follow-up CT image. Only the ILA status on baseline CT images was associated with radiologic ILA progression.
The prevalence of ILAs in the present study was 9.5%. This is consistent with a previous study by Hida et al., who reported a 9.5% prevalence among patients with stage I non-small cell lung cancer (NSCLC) [11]. Other large cohort studies or lung cancer screening cohorts have revealed a 7–10% prevalence [1,3]. However, the ILA prevalence among patients with lung cancer varies from 3.9% among patients with stage IV NSCLC, as reported by Araki et al. [14], to 21.7% among patients with stage I and II lung cancer, as reported by Iwasawa et al. [15]. Nishino et al. [16] reported an ILA prevalence of 14% among patients with stage IV NSCLC. Several factors could account for these variations in ILA prevalence. Different studies focus on patients with varying stages and types of lung cancer, which could influence ILA prevalence. The proportion of smokers in the study cohort can vary, potentially affecting ILA rates. Other factors such as age, gender, comorbidities, and environmental exposures might also have influence ILA prevalence. Additionally, the diagnosis of ILA can be subjective, leading to potential variability in interpretation among radiologists.
To the best of our knowledge, this is the first study in which ILA progression was investigated in patients with lung cancer. ILAs have garnered much attention in patients with lung cancer owing to their potential impact on treatment outcomes and mortality. They are associated with an increased risk of postoperative complications, immune-related pneumonitis, and radiation pneumonitis, as well as increased mortality [8,9,10,15,17]. However, a gap exists in the understanding of the natural course of radiologic ILA progression.
Several studies have been conducted to investigate ILA progression rates in large cohorts and lung cancer screening populations. Patel et al. reported that 24.4% (10/41) of patients with ILAs on baseline CT images in a lung cancer screening cohort were later diagnosed with ILD [18]. The progression of ILAs was estimated to be approximately 20% (16/79) over 2 years in the NLST and 25% (3/12) with other chronic interstitial pneumonia patterns over 3 years in the Multicentric Italian Lung Detection trials [3,19]. With a longer follow-up period, >40% of ILAs progress over 5 years [6]. A study involving an Asian health screening cohort revealed an ILA progression rate of 80% (48/60) over 8 years [5]. However, the natural course of ILAs after treating patients with lung cancer remains unclear. The present study uniquely addresses this gap by offering clinicians insights that can influence pre-treatment risk stratification and postoperative follow-up planning, potentially affecting treatment outcomes.
The progression rates observed in our study population seemed higher than those previously reported in general or lung cancer screening cohorts. We hypothesized that patients with lung cancer may represent a high-risk group for ILA progression owing to their exposure to various treatment methods, such as surgery, chemotherapy, and radiotherapy, which may accelerate ILA progression. Given the study’s methodology, classifying even slight changes as progression, the progression rate might have been overestimated. Nonetheless, the subsequent ILD diagnoses in 19.2% of the patients with fibrotic ILAs remain a clinically significant finding. Given the notable progression rates observed, it would be advisable for clinicians to include a focused evaluation of ILA progression during the follow-up assessments, especially those with baseline ILA. Furthermore, by educating patients about the potential risks of ILA progression, they can be better prepared to promptly report any new or worsening respiratory symptoms.
This study had several limitations. First, a selection bias might have occurred owing to the study’s retrospective nature. Second, the correlation between the radiologic progression of ILAs and clinical symptoms, such as dyspnea or decreased lung function, during the follow-up period was not investigated. Many patients did not undergo regular pulmonary function tests after surgery, and the documentation of patients’ symptoms in the electronic medical records (EMR) was inconsistent. Recognizing this, we believe that future research in this area would benefit from prospective studies that ensure accurate and consistent recording of patients’ clinical symptoms and outcomes. Third, only qualitative image analyses were performed. Hence, the degree of radiologic progression could not be adequately assessed. Consequently, even mild progression, which does not necessarily indicate clinically significant disease progression, might have been classified as progression. Additionally, ILA scoring may vary among radiologists. Further studies with quantitative analysis may provide better reproducibility and more detailed assessments of ILA progression. Furthermore, a systematic evaluation of the correlation between clinical symptoms and radiologic features is warranted to determine the impact of ILAs on patient outcomes.
In conclusion, the ILAs and equivocal ILAs detected on CT images at lung cancer diagnosis were associated with ILA progression after surgical resection for lung cancer. Hence, early identification of ILAs and an understanding of their implications are essential, and heightened awareness and monitoring are recommended to ensure optimal patient care and management.
Supplementary Materials
The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/jcm12216858/s1. Table S1. Baseline characteristics and clinical events according to ILA status of patients (n = 346) and ILA progression rates with detailed information.
Author Contributions
Conceptualization, S.Y.A.; Formal analysis, D.S.; Investigation, Y.J.S. and S.Y.A.; Writing—original draft, Y.J.S. and S.Y.A.; Writing—review & editing, J.G.Y., M.Y.K. and S.Y.A. All authors have read and agreed to the published version of the manuscript.
Funding
This work was supported by the Konkuk University Medical Center Research Grant 2023.
Institutional Review Board Statement
The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Institutional Review Board of Konkuk University Medical Center (KUMC 2023-06-050).
Informed Consent Statement
The requirement for informed consent was waived by the Institutional Review Board.
Data Availability Statement
The datasets generated during and/or analyzed during the current study are available from the corresponding author upon reasonable request.
Conflicts of Interest
The authors declare no conflict of interest.
References
- Putman, R.K.; Hatabu, H.; Araki, T.; Gudmundsson, G.; Gao, W.; Nishino, M.; Okajima, Y.; Dupuis, J.; Latourelle, J.C.; Cho, M.H.; et al. Association between interstitial lung abnormalities and all-cause mortality. JAMA 2016, 315, 672–681. [Google Scholar] [CrossRef] [PubMed]
- Hatabu, H.; Hunninghake, G.M.; Richeldi, L.; Brown, K.K.; Wells, A.U.; Remy-Jardin, M.; Verschakelen, J.; Nicholson, A.G.; Beasley, M.B.; Christiani, D.C.; et al. Interstitial lung abnormalities detected incidentally on CT: A Position Paper from the Fleischner Society. Lancet Respir. Med. 2020, 8, 726–737. [Google Scholar] [CrossRef] [PubMed]
- Jin, G.Y.; Lynch, D.; Chawla, A.; Garg, K.; Tammemagi, M.C.; Sahin, H.; Misumi, S.; Kwon, K.S. Interstitial lung abnormalities in a CT lung cancer screening population: Prevalence and progression rate. Radiology 2013, 268, 563–571. [Google Scholar] [CrossRef] [PubMed]
- Araki, T.; Putman, R.K.; Hatabu, H.; Gao, W.; Dupuis, J.; Latourelle, J.C.; Nishino, M.; Zazueta, O.E.; Kurugol, S.; Ross, J.C.; et al. Development and progression of interstitial lung abnormalities in the Framingham heart study. Am. J. Respir. Crit. Care Med. 2016, 194, 1514–1522. [Google Scholar] [CrossRef] [PubMed]
- Lee, J.E.; Chae, K.J.; Suh, Y.J.; Jeong, W.G.; Lee, T.; Kim, Y.H.; Jin, G.Y.; Jeong, Y.J. Prevalence and long-term outcomes of CT interstitial lung abnormalities in a health screening cohort. Radiology 2023, 306, e221172. [Google Scholar] [CrossRef] [PubMed]
- Putman, R.K.; Gudmundsson, G.; Axelsson, G.T.; Hida, T.; Honda, O.; Araki, T.; Yanagawa, M.; Nishino, M.; Miller, E.R.; Eiriksdottir, G.; et al. Imaging patterns are associated with interstitial lung abnormality progression and mortality. Am. J. Respir. Crit. Care Med. 2019, 200, 175–183. [Google Scholar] [CrossRef] [PubMed]
- Axelsson, G.T.; Putman, R.K.; Aspelund, T.; Gudmundsson, E.F.; Hida, T.; Araki, T.; Nishino, M.; Hatabu, H.; Gudnason, V.; Hunninghake, G.M.; et al. The associations of interstitial lung abnormalities with cancer diagnoses and mortality. Eur. Respir. J. 2020, 56, 1902154. [Google Scholar] [CrossRef] [PubMed]
- Im, Y.; Chung, M.P.; Lee, K.S.; Han, J.; Chung, M.J.; Kim, H.K.; Cho, J.H.; Choi, Y.S.; Park, S.; Kim, H.J.; et al. Impact of interstitial lung abnormalities on postoperative pulmonary complications and survival of lung cancer. Thorax 2023, 78, 183–190. [Google Scholar] [CrossRef] [PubMed]
- Onishi, H.; Yamashita, H.; Shioyama, Y.; Matsumoto, Y.; Takayama, K.; Matsuo, Y.; Miyakawa, A.; Matsushita, H.; Aoki, M.; Nihei, K.; et al. Stereotactic body radiation therapy for patients with pulmonary interstitial change: High incidence of fatal radiation pneumonitis in a retrospective multi-institutional study. Cancers 2018, 10, 257. [Google Scholar] [CrossRef] [PubMed]
- Jeong, W.G.; Kim, Y.H.; Lee, J.E.; Oh, I.J.; Song, S.Y.; Chae, K.J.; Park, H.M. Predictive value of interstitial lung abnormalities for postoperative pulmonary complications in elderly patients with early-stage lung cancer. Cancer Res. Treat. 2022, 54, 744–752. [Google Scholar] [CrossRef] [PubMed]
- Hida, T.; Hata, A.; Lu, J.; Valtchinov, V.I.; Hino, T.; Nishino, M.; Honda, H.; Tomiyama, N.; Christiani, D.C.; Hatabu, H. Interstitial lung abnormalities in patients with stage I non-small cell lung cancer are associated with shorter overall survival: The Boston lung cancer study. Cancer Imaging 2021, 21, 14. [Google Scholar] [CrossRef] [PubMed]
- Washko, G.R.; Lynch, D.A.; Matsuoka, S.; Ross, J.C.; Umeoka, S.; Diaz, A.; Sciurba, F.C.; Hunninghake, G.M.; San José Estépar, R.; Silverman, E.K.; et al. Identification of early interstitial lung disease in smokers from the COPDGene Study. Acad. Radiol. 2010, 17, 48–53. [Google Scholar] [CrossRef] [PubMed]
- Chae, K.J.; Chung, M.J.; Jin, G.Y.; Song, Y.J.; An, A.R.; Choi, H.; Goo, J.M. Radiologic-pathologic correlation of interstitial lung abnormalities and predictors for progression and survival. Eur. Radiol. 2022, 32, 2713–2723. [Google Scholar] [CrossRef] [PubMed]
- Araki, T.; Dahlberg, S.E.; Hida, T.; Lydon, C.A.; Rabin, M.S.; Hatabu, H.; Johnson, B.E.; Nishino, M. Interstitial lung abnormality in stage IV non-small cell lung cancer: A validation study for the association with poor clinical outcome. Eur. J. Radiol. Open 2019, 6, 128–131. [Google Scholar] [CrossRef]
- Iwasawa, T.; Okudela, K.; Takemura, T.; Fukuda, T.; Matsushita, S.; Baba, T.; Ogura, T.; Tajiri, M.; Yoshizawa, A. Computer-aided quantification of pulmonary fibrosis in patients with lung cancer: Relationship to disease-free survival. Radiology 2019, 292, 489–498. [Google Scholar] [CrossRef]
- Nishino, M.; Cardarella, S.; Dahlberg, S.E.; Araki, T.; Lydon, C.; Jackman, D.M.; Rabin, M.S.; Hatabu, H.; Johnson, B.E. Interstitial lung abnormalities in treatment-naïve advanced non-small-cell lung cancer patients are associated with shorter survival. Eur. J. Radiol. 2015, 84, 998–1004. [Google Scholar] [CrossRef] [PubMed]
- Chen, X.; Li, Z.; Wang, X.; Zhou, J.; Wei, Q.; Jiang, R. Association of pre-existing lung interstitial changes with immune-related pneumonitis in patients with non-small lung cancer receiving immunotherapy. Support Care Cancer 2022, 30, 6515–6524. [Google Scholar] [CrossRef] [PubMed]
- Patel, A.S.; Miller, E.; Regis, S.M.; Hunninghake, G.M.; Price, L.L.; Gawlik, M.; McKee, A.B.; Rieger-Christ, K.M.; Pinto-Plata, V.; Liesching, T.N.; et al. Interstitial lung abnormalities in a large clinical lung cancer screening cohort: Association with mortality and ILD diagnosis. Respir. Res. 2023, 24, 49. [Google Scholar] [CrossRef] [PubMed]
- Sverzellati, N.; Guerci, L.; Randi, G.; Calabrò, E.; La Vecchia, C.; Marchianò, A.; Pesci, A.; Zompatori, M.; Pastorino, U. Interstitial lung diseases in a lung cancer screening trial. Eur. Respir. J. 2011, 38, 392–400. [Google Scholar] [CrossRef] [PubMed]
Figure 1.
Flowchart of patient selection. CT, computed tomography; ILA, interstitial lung abnormality; ILD, interstitial lung disease.
Figure 1.
Flowchart of patient selection. CT, computed tomography; ILA, interstitial lung abnormality; ILD, interstitial lung disease.
Figure 2.
Baseline and 4-year follow-up chest computed tomography images Baseline (a,c,e) and 4-year follow-up (b,d,f) chest CT images in the upper (a,b), middle (c,d), and lower (e,f) lung zones of a 56-year-old, male current smoker with a 60 pack-year smoking history. The baseline CT reveals subpleural reticulation and mild traction bronchiolectasis in both lungs, suggesting the presence of fibrotic ILAs. A 1.5 cm-sized nodule (arrow) was identified in the right upper lobe and confirmed as adenocarcinoma (a). The patient underwent right upper lobe lobectomy and adjuvant chemotherapy with cisplatin and paclitaxel. The 4-year follow-up CT reveals increased subpleural reticulation, traction bronchiectasis, and honeycombing (box), predominantly in lower lung zones, indicating ILA progression.
Figure 2.
Baseline and 4-year follow-up chest computed tomography images Baseline (a,c,e) and 4-year follow-up (b,d,f) chest CT images in the upper (a,b), middle (c,d), and lower (e,f) lung zones of a 56-year-old, male current smoker with a 60 pack-year smoking history. The baseline CT reveals subpleural reticulation and mild traction bronchiolectasis in both lungs, suggesting the presence of fibrotic ILAs. A 1.5 cm-sized nodule (arrow) was identified in the right upper lobe and confirmed as adenocarcinoma (a). The patient underwent right upper lobe lobectomy and adjuvant chemotherapy with cisplatin and paclitaxel. The 4-year follow-up CT reveals increased subpleural reticulation, traction bronchiectasis, and honeycombing (box), predominantly in lower lung zones, indicating ILA progression.
Table 1.
Baseline characteristics and clinical events according to ILA status of patients (n = 346) and ILA progression rates.
Table 1.
Baseline characteristics and clinical events according to ILA status of patients (n = 346) and ILA progression rates.
| ILA Status on Baseline CT | ||||||
|---|---|---|---|---|---|---|
| Variables | Total (n = 346) | No ILA (n = 291) | Equivocal ILA (n = 22) | p | ILA (n = 33) | p |
| Age | 67 (60.25, 74) | 66 (59, 72) | 76.5 (73, 77) | <0.001 | 75 (69, 78) | <0.001 |
| Sex | ||||||
| M | 204 (59.0) | 161 (55.3) | 14 (63.6) | 0.449 | 29 (87.9) | <0.001 |
| F | 142 (41.0) | 130 (44.7) | 8 (36.4) | 4 (12.1) | ||
| Smoking (n = 341) | ||||||
| Never | 146 (42.8) | 136 (47.4) | 6 (27.3) | 0.085 | 4 (12.5) | 0.001 |
| Former | 110 (32.3) | 82 (28.6) | 11 (50.0) | 17 (53.1) | ||
| Current | 85 (24.9) | 69 (24.0) | 5 (22.7) | 11 (34.4) | ||
| Operation type | ||||||
| Lobectomy | 247 (71.4) | 216 (74.2) | 13 (59.1) | 0.187 | 18 (54.5) | 0.051 |
| Pneumonectomy | 5 (1.4) | 3 (1.0) | 1 (4.5) | 1 (3.0) | ||
| Segmentectomy | 4 (1.2) | 4 (1.4) | 0 (0.0) | 0 (0.0) | ||
| Wedge | 90 (26.0) | 68 (23.4) | 8 (36.4) | 14 (42.4) | ||
| No. of operations | ||||||
| 1 | 320 (92.5) | 270 (92.8) | 22 (100.0) | 0.380 | 28 (84.8) | 0.164 |
| ≥2 | 26 (7.5) | 21 (7.2) | 0 (0.0) | 5 (15.2) | ||
| Size (cm) | 2.3 (1.7, 3.3) | 2.4 (1.7, 3.25) | 2.1 (1.83, 2.77) | 0.937 | 2.2 (1.5, 3.5) | 0.733 |
| Nodule type | ||||||
| Solid | 198 (57.2) | 156 (53.6) | 16 (72.7) | 0.160 | 26 (78.8) | 0.017 |
| PSN | 126 (36.4) | 115 (39.5) | 6 (27.3) | 5 (15.2) | ||
| Pure GGN | 22 (6.4) | 20 (6.9) | 0 (0.0) | 2 (6.1) | ||
| Diagnosis | ||||||
| ADC | 276 (79.8) | 248 (85.2) | 14 (63.6) | 0.018 | 14 (42.4) | <0.001 |
| SQCC | 57 (16.5) | 35 (12.0) | 6 (27.3) | 16 (48.5) | ||
| Others | 13 (3.8) | 8 (2.7) | 2 (9.1) | 3 (9.1) | ||
| Stage | ||||||
| 1 | 236 (68.2) | 194 (66.7) | 16 (72.7) | 0.114 | 26 (78.8) | 0.194 |
| 2 | 42 (12.1) | 32 (11.0) | 5 (22.7) | 5 (15.2) | ||
| 3 | 34 (9.8) | 33 (11.3) | 0 (0.0) | 1 (3.0) | ||
| 4 | 34 (9.8) | 32 (11.0) | 1 (4.5) | 1 (3.0) | ||
| Anticancer drugs | ||||||
| No | 180 (52.0) | 152 (52.2) | 12 (54.5) | 0.834 | 16 (48.5) | 0.683 |
| Yes | 166 (48.0) | 139 (47.8) | 10 (45.5) | 17 (51.5) | ||
| Radiotherapy | ||||||
| No | 313 (90.5) | 266 (91.4) | 20 (90.9) | 1.000 | 27 (81.8) | 0.109 |
| Yes | 33 (9.5) | 25 (8.6) | 2 (9.1) | 6 (18.2) | ||
| ILD diagnosis | ||||||
| No | 340 (98.3) | 291 (100.0) | 21 (95.5) | 0.070 | 28 (84.8) | <0.001 |
| Yes | 6 (1.7) | 0 (0.0) | 1 (4.5) | 5 (15.2) | ||
| ILA progression | ||||||
| Stable | 304 (87.9) | 285 (97.9) | 11 (50.0) | <0.001 | 8 (24.2) | <0.001 |
| Progression | 42 (12.1) | 6 (2.1) | 11 (50.0) | 25 (75.8) | ||
| Follow-up interval (days) | 1312.5 (944.5, 1682.75) | 1316 (944, 1702) | 1389.5 (1103.25, 1508) | 0.699 | 1254 (913, 1657) | 0.443 |
Continuous values are presented as medians (Q1, Q3) and tested using the Wilcoxon rank-sum test. Categorical values are presented as n (%) and tested using the chi-squared or Fisher’s exact tests. p < 0.025 for statistical significance, taking into account Bonferroni correction by a number of comparisons (no ILAs vs. equivocal ILAs and no ILAs vs. ILAs) (0.05/2). ILA, interstitial lung abnormality; CT, computed tomography; M, male; F, female; ILD, interstitial lung disease; PY, pack-years; FVC, forced vital capacity; FEV1, forced expiratory volume in the first second; PSN, part-solid nodule; GGN, ground glass nodule; ADC, adenocarcinoma; SQCC, squamous cell carcinoma.
Table 2.
Risk factors for ILA progression in patients with lung cancer after surgical resection.
| Univariate Analysis | Multivariate Analysis (n = 341) | |||||
|---|---|---|---|---|---|---|
| Unadjusted OR | 95% CI | p | Adjusted OR | 95% CI | p | |
| Age | 1.101 | 1.055–1.153 | <0.001 | 1.024 | 0.952–1.109 | 0.548 |
| Sex | ||||||
| M | Ref. | Ref. | ||||
| F | 0.351 | 0.153–0.729 | 0.008 | 1.736 | 0.278–11.899 | 0.563 |
| Smoking | ||||||
| Never | Ref. | Ref. | ||||
| Former | 3.885 | 1.623–10.333 | 0.004 | 1.895 | 0.275–13.109 | 0.513 |
| Current | 4.605 | 1.873–12.465 | 0.001 | 4.497 | 0.534–45.689 | 0.182 |
| PY | 1.018 | 1.006–1.031 | 0.003 | |||
| 0 | Ref. | |||||
| 0 < PY ≤ 30 | 3.919 | 1.581–10.652 | 0.004 | |||
| >30 | 5.030 | 2.107–13.378 | 0.001 | |||
| Operation type | ||||||
| Lobectomy+ Pneumonectomy | Ref. | Ref. | ||||
| Wedge+ Segmentectomy | 2.005 | 1.014–3.889 | 0.041 | 1.273 | 0.409–3.891 | 0.671 |
| No. of operation | ||||||
| 1 | Ref. | |||||
| ≥2 | 1.349 | 0.380–3.760 | 0.599 | |||
| Size | 0.994 | 0.759–1.270 | 0.963 | |||
| Nodule type | ||||||
| Solid | Ref. | Ref. | ||||
| PSN | 0.399 | 0.174–0.835 | 0.020 | 1.295 | 0.372–4.557 | 0.682 |
| Pure GGN | 0.247 | 0.014–1.248 | 0.179 | 0.000 | 0.000–Inf | 0.989 |
| Diagnosis | ||||||
| ADC | Ref. | Ref. | ||||
| SQCC | 6.243 | 3.008–12.992 | <0.001 | 1.543 | 0.409–5.734 | 0.516 |
| Others | 8.454 | 2.364–27.991 | 0.001 | 3.914 | 0.445–31.152 | 0.209 |
| Stage | ||||||
| 1 | Ref. | |||||
| 2 | 1.025 | 0.366–2.472 | 0.958 | |||
| 3 | 0.186 | 0.010–0.914 | 0.104 | |||
| 4 | 0.384 | 0.061–1.353 | 0.204 | |||
| Anticancer drugs | ||||||
| No | Ref. | |||||
| Yes | 1.222 | 0.640–2.347 | 0.543 | |||
| Adjuvant cytotoxic chemotherapy | ||||||
| No anticancer drugs | Ref. | |||||
| Yes | 1.291 | 0.656–2.514 | 0.453 | |||
| No | 0.680 | 0.105–2.523 | 0.617 | |||
| Adjuvant oncogene-targeted | ||||||
| No anticancer drugs | Ref. | |||||
| Yes | 0.434 | 0.100–1.316 | 0.189 | |||
| No | 1.704 | 0.848–3.379 | 0.128 | |||
| Adjuvant immunotherapy | ||||||
| No anticancer drugs | Ref. | Ref. | ||||
| Yes | 2.736 | 0.982–6.992 | 0.042 | 2.808 | 0.481–15.493 | 0.241 |
| No | 0.907 | 0.429–1.853 | 0.793 | 1.181 | 0.357–3.890 | 0.782 |
| Radiotherapy | ||||||
| No | Ref. | |||||
| Yes | 1.710 | 0.606–4.182 | 0.269 | |||
| Baseline ILA status | ||||||
| No ILA | Ref. | Ref. | ||||
| Equivocal ILA | 47.500 | 15.405–162.218 | <0.001 | 35.964 | 10.033–147.398 | <0.001 |
| Nonfibrotic ILA | 118.750 | 21.309–961.923 | <0.001 | 200.862 | 22.823–4595.382 | <0.001 |
| Fibrotic ILA | 158.333 | 50.517–592.398 | <0.001 | 114.855 | 29.377–561.518 | <0.001 |
Variables with p-values < 0.5 in the univariate analyses were included in the multivariable analysis. OR, odds ratio; CI, confidence interval; Ref., reference.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
MDPI and ACS Style
Shin, Y.J.; Yi, J.G.; Kim, M.Y.; Son, D.; Ahn, S.Y. Radiologic Progression of Interstitial Lung Abnormalities following Surgical Resection in Patients with Lung Cancer. J. Clin. Med. 2023, 12, 6858. https://doi.org/10.3390/jcm12216858
AMA Style
Shin YJ, Yi JG, Kim MY, Son D, Ahn SY. Radiologic Progression of Interstitial Lung Abnormalities following Surgical Resection in Patients with Lung Cancer. Journal of Clinical Medicine. 2023; 12(21):6858. https://doi.org/10.3390/jcm12216858
Chicago/Turabian StyleShin, Yoon Joo, Jeong Geun Yi, Mi Young Kim, Donghee Son, and Su Yeon Ahn. 2023. "Radiologic Progression of Interstitial Lung Abnormalities following Surgical Resection in Patients with Lung Cancer" Journal of Clinical Medicine 12, no. 21: 6858. https://doi.org/10.3390/jcm12216858
APA StyleShin, Y. J., Yi, J. G., Kim, M. Y., Son, D., & Ahn, S. Y. (2023). Radiologic Progression of Interstitial Lung Abnormalities following Surgical Resection in Patients with Lung Cancer. Journal of Clinical Medicine, 12(21), 6858. https://doi.org/10.3390/jcm12216858
Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.
